PYX Resources: Achieving volume and diversification milestones. Watch the video here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAVI Global Trust Regulatory News (AGT)

Share Price Information for AVI Global Trust (AGT)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 244.50
Bid: 191.00
Ask: 0.00
Change: 0.00 (0.00%)
Spread: 54.00 (28.272%)
Open: 0.00
High: 0.00
Low: 0.00
Prev. Close: 244.50
AGT Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Monthly Factsheet

11 Oct 2023 15:27

RNS Number : 8282P
AVI Global Trust PLC
11 October 2023

AVI GLOBAL TRUST PLC

Monthly Update

AVI Global Trust plc (the "Company") presents its Update, reporting performance figures for the month ended 30 September 2023.

This Monthly Newsletter is available on the Company's website at:

https://www.assetvalueinvestors.com/content/uploads/2023/10/AGT-SEPTEMBER-2023.pdf

Performance Total Return

This investment management report relates to performance figures to 30 September 2023.

Total Return (£)

Month

Calendar Yr

to date

1Y

3Y

5Y

10Y

AGT NAV

2.4%

9.8%

15.3%

45.6%

48.7%

149.3%

MSCI ACWI Ex US

0.5%

3.8%

10.1%

18.2%

21.3%

84.4%

MSCI ACWI

-0.5%

8.5%

10.5%

29.4%

46.1%

174.9%

Manager's Comment

AVI Global Trust (AGT)'s NAV increased by +2.4% in September.

Schibsted (+7%), Symphony International (+21%) and Apollo (+3%) were the most significant contributors, with an additional tailwind from Sterling weakness. Our hedged trade at Brookfield Corp was the most significant detractor (-33bps) as the discount widened. Christian Dior and FEMSA also detracted.

September marks the end of AGT's financial year. For FY23 AGT achieved a NAV total return of +15.3%. This compares to a +10.1% return for the MSCI AC World ex-US index and a +10.5% return for the broader MSCI AC World Index (all figures in GBP).

Performance has been driven by stock selection - something we believe is coming back to the fore. Our high conviction larger weight holdings, such as Apollo, KKR, FEMSA and Schibsted, have on average performed better.

The latter two are good examples of the types of idiosyncratic "events" to which we are attracted - where management teams and boards are undertaking strategic and structural changes to unlock value. As well as this we are particularly excited about opportunities where we can unlock value as engaged shareholders, both in the London listed closed-end fund market where discounts have widened considerably, and in Japan, where we continue to find attractive opportunities.

We maintain that the outlook for equities en-masse is arguably a challenging one. This is throwing up a rich and varied opportunity set within the areas of the equity market that we focus on. We are optimistic about our ability to exploit these opportunities and drive attractive long-term returns.

The annual report is due to be published in early November, and the AGM will be held on the 20th of December.

Schibsted B

Shares in Schibsted rose +7% over the month as a key part of our investment thesis started to play out. We will provide an update here notwithstanding the numerous unknowns at the time of writing.

As a reminder, we initiated a position in the summer of 2022. We wrote up the investment in the September 2022 newsletter, highlighting the extreme undervaluation of Schibsted, with its then 33% listed stake in Adevinta swamping its enterprise value.

Overall, we argued that Schibsted exhibited a number of attributes we look for - high quality assets, a discounted valuation and catalysts to unlock value. More specially, Schibsted offers 1) exposure to high quality online classified ads businesses which have dominant market positions protected by a powerful network effect, high levels of pricing power and strong margin expansion potential which should compound in value; 2) an inefficient and unsuitable group structure leading the company to trade at a wide discount to NAV and the stub at an inordinately low (then) c.6x EV/EBITDA; and 3) potential catalysts to unlock value, with either an in specie distribution or sale of Adevinta suitable outcomes to both re-rate the stub and help realise Adevinta's fair value.

During the month it was confirmed that Blackrock and Permira made a non-binding proposal to take Adevinta private. This will see Schibsted crystalise a large portion of its value, whilst also retaining a stake in the private company. Of course, the devil will be in the detail, with the pertinent questions being around price and the size of the stake that Schibsted will maintain, but we believe this to be a successful outcome.

The deal will allow Schibsted to garner a control premium (albeit an unknown one at this stage) and removes some of the friction of an in-specie distribution. Most importantly, it will simplify the group structure and shine a light on the undervaluation of the stub assets.

On the other hand, this raises the risk of capital (mis)allocation - something we will continue to discuss with Schibsted management. We are also frank about the low value the market will likely ascribe to Schibsted's remaining unlisted stake in Adevinta. However, we very much concede that the return on this position has the potential to be highly attractive, with significant low hanging fruit from non-core asset sales (OLX Brazil plus Italy and maybe Spain); improving monetisation rates at Mobile and Leboncoin which currently under-earn relative to global peers and the economic utility they provide; and improving margins with tighter cost control (particularly at HQ which runs to the tune of ~?250m p.a.). Over time this value creation will shine through in Schibsted's NAV growth, with a future crystallisation of value likely allowing for capital returns.

Schibsted remains cheaply valued at a 34% discount to NAV and with the stub trading at 6.7x NTM EBITDA. Further news on Adevinta will be the key catalyst to drive both NAV and discounts. We remain excited about prospective returns.

Symphony International

Shares in Symphony International rose +21% in September as the company announced an "orderly realisation" of its portfolio.

Long-term readers of our newsletters will know that, as the largest independent shareholder, we have worked to improve corporate governance at the company and unlock value trapped in the persistently wide discount at which the company has traded. This culminated in a 2021 public campaign to Save Symphony.

We view this as a pleasing outcome and will be following the realisation process closely to ensure shareholder value is optimised.

Contributors / Detractors (in GBP)

Largest Contributors

1- month contribution

bps

% Weight

Schibsted B

84

8.5

Symphony International

63

3.1

Apollo Global

37

5.8

Godrej Industries

29

3.3

D'Ieteren

28

4.0

Largest Detractors

1- month contribution

bps

% Weight

Brookfield Corporation

-34

5.1

Christian Dior

-27

2.0

IAC

-19

3.3

Digital Garage

-12

1.6

Molten Ventures

-12

1.7

Link Company Matters Limited

Corporate Secretary

11 October 2023

LEI: 213800QUODCLWWRVI968

The content of the Company's web-pages and the content of any website or pages which may be accessed through hyperlinks on the Company's web-pages, other than the content of the Newsletter referred to above, is neither incorporated into nor forms part of the above announcement.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
END
DOCGPGWPUUPWGCG
Date   Source Headline
15th Jun 202312:45 pmRNSNet Asset Value(s)
14th Jun 20231:26 pmRNSNet Asset Value(s)
14th Jun 202310:33 amRNSDirector/PDMR Shareholding
13th Jun 202312:26 pmRNSNet Asset Value(s)
12th Jun 202312:56 pmRNSNet Asset Value(s)
9th Jun 20232:46 pmRNSNet Asset Value(s)
8th Jun 20232:27 pmRNSNet Asset Value(s)
7th Jun 20234:39 pmRNSMonthly Factsheet
7th Jun 20232:58 pmRNSNet Asset Value(s)
6th Jun 20231:24 pmRNSNet Asset Value(s)
5th Jun 20232:52 pmRNSNet Asset Value(s)
2nd Jun 20233:58 pmRNSNet Asset Value(s)
1st Jun 20235:32 pmRNSTransaction in Own Shares
1st Jun 20233:41 pmRNSNet Asset Value(s)
1st Jun 20237:00 amRNSTotal Voting Rights
1st Jun 20237:00 amRNSHalf-year Report
31st May 20235:19 pmRNSTransaction in Own Shares
31st May 20235:08 pmRNSHolding(s) in Company
31st May 20232:34 pmRNSNet Asset Value(s)
30th May 20235:19 pmRNSTransaction in Own Shares
30th May 20233:28 pmRNSNet Asset Value(s)
26th May 20235:27 pmRNSTransaction in Own Shares
26th May 20231:49 pmRNSNet Asset Value(s)
25th May 20235:30 pmRNSTransaction in Own Shares
25th May 20232:19 pmRNSNet Asset Value(s)
24th May 20235:24 pmRNSTransaction in Own Shares
24th May 20231:55 pmRNSNet Asset Value(s)
23rd May 20235:48 pmRNSTransaction in Own Shares
23rd May 20233:20 pmRNSNet Asset Value(s)
22nd May 20235:24 pmRNSTransaction in Own Shares
22nd May 20231:30 pmRNSNet Asset Value(s)
19th May 20235:44 pmRNSTransaction in Own Shares
19th May 20232:49 pmRNSNet Asset Value(s)
18th May 20235:21 pmRNSTransaction in Own Shares
18th May 20232:16 pmRNSNet Asset Value(s)
17th May 20231:32 pmRNSNet Asset Value(s)
16th May 20235:59 pmRNSTransaction in Own Shares
16th May 20233:47 pmRNSNet Asset Value(s)
15th May 20235:26 pmRNSTransaction in Own Shares
15th May 20232:08 pmRNSNet Asset Value(s)
12th May 20232:14 pmRNSNet Asset Value(s)
11th May 20235:44 pmRNSTransaction in Own Shares
11th May 202312:18 pmRNSNet Asset Value(s)
10th May 20235:28 pmRNSTransaction in Own Shares
10th May 20233:50 pmRNSMonthly Factsheet
10th May 202312:52 pmRNSNet Asset Value(s)
9th May 20235:15 pmRNSTransaction in Own Shares
9th May 20231:51 pmRNSNet Asset Value(s)
5th May 20236:18 pmRNSTransaction in Own Shares
5th May 202312:22 pmRNSNet Asset Value(s)

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.